A First in Man Study of MABp1 in Patients With Advanced Cancers
Status:
Completed
Trial end date:
2013-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to block interleukin-1 alpha activity with a True Human
monoclonal antibody, thus interrupting the inflammatory response that supports tumor
growth/metastasis and which drives the cachexic process.
An adaptive design will be employed which will allow for the exploration of different dosing
regimens, as well as tumor types that show preliminary evidence of efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC XBiotech, Inc.